Results 21 to 30 of about 4,886 (183)

Easy to say, hard to do. To the anniversary of two fundamental discoveries. Part 2

Трансплантология (Москва), 2022
On the eve of the anniversaries of two historical events: the 145th anniversary of the experiments in which Eck's fistula was performed and the 55th anniversary of the successful clinical approbation of the selective distal splenorenal anastomosis, a ...
A. Yu. Anisimov
doaj   +1 more source

Golexanolone, a GABAA receptor modulating steroid antagonist, restores motor coordination and cognitive function in hyperammonemic rats by dual effects on peripheral inflammation and neuroinflammation

CNS Neuroscience &Therapeutics, Volume 28, Issue 11, Page 1861-1874, November 2022., 2022
Immunotherapy has emerged as a promising treatment for GBM patients. The impact of several molecular and clinical variables on survival outcomes of GBM patients treated with immunotherapy has been comprehensively assessed in this systematic review and meta‐analysis.
Gergana Mincheva, Carla Gimenez‐Garzo, Paula Izquierdo‐Altarejos, Mar Martinez‐Garcia, Magnus Doverskog, Thomas P. Blackburn, Anneli Hällgren, Torbjörn Bäckström, Marta Llansola, Vicente Felipo   +9 more
wiley   +1 more source

A comprehensive review of prognostic scoring systems to predict survival after transjugular intrahepatic portosystemic shunt placement

Portal Hypertension &Cirrhosis, Volume 1, Issue 2, Page 133-144, September 2022., 2022
Prognostic tools for survival prediction and risk stratification after transjugular intrahepatic portosystemic shunt placement. Abstract Patient prognosis after transjugular intrahepatic portosystemic shunt (TIPS) placement is relatively poor and highly heterogeneous; therefore, a prognostic scoring system is essential for survival prediction and risk ...
Chongtu Yang, Bin Xiong
wiley   +1 more source

Preoperative portal vein recanalization–transjugular intrahepatic portosystemic shunt for chronic obliterative portal vein thrombosis: Outcomes following liver transplantation

Hepatology Communications, Volume 6, Issue 7, Page 1803-1812, July 2022., 2022
Patients with chronic, obliterative portal vein thrombosis may be converted to liver transplantation candidacy following portal vein recanalization‐transjugular intrahepatic portosystemic shunt (PVR‐TIPS). Long‐term survival outcomes of patients with chronic, obliterative portal vein thrombosis who undergo transplantation following PVR‐TIPS are similar
Abhinav Talwar, Jeffrey Varghese, Gabriel M. Knight, Nitin Katariya, Juan‐Carlos Caicedo, Zach Dietch, Daniel Borja‐Cacho, Daniella Ladner, Derrick Christopher, Talia Baker, Michael Abecassis, Samdeep Mouli, Kush Desai, Ahsun Riaz, Bart Thornburg, Riad Salem   +15 more
wiley   +1 more source

Easy to say, hard to do. To the anniversary of two fundamental discoveries. Part 3

Трансплантология (Москва), 2023
On the eve of the anniversaries of two historical events: the 145th anniversary of the experiments in which Eck's fistula was performed and the 55th anniversary of the successful clinical approbation of the selective distal splenorenal anastomosis, a ...
A. Yu. Anisimov
doaj   +1 more source

Evaluation of the Pharmacokinetics and Safety of a Single Dose of Acalabrutinib in Subjects With Hepatic Impairment

The Journal of Clinical Pharmacology, Volume 62, Issue 6, Page 812-822, June 2022., 2022
Abstract Acalabrutinib received approval for the treatment of adult patients with mantle cell lymphoma who received at least 1 prior therapy and adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. This study investigated the impact of hepatic impairment (HI) on acalabrutinib pharmacokinetics (PK) and safety at a single 50‐mg
Yan Xu, Raquel Izumi, Helen Nguyen, Anna Kwan, Howard Kuo, Jeannine Madere, J. Greg Slatter, Terry Podoll, Karthick Vishwanathan, Thomas Marbury, William Smith, Richard A. Preston, Shringi Sharma, Joseph A. Ware   +13 more
wiley   +1 more source

Positive GABAA receptor modulating steroids and their antagonists: Implications for clinical treatments

Journal of Neuroendocrinology, Volume 34, Issue 2, February 2022., 2022
GABA is the major inhibitory moderating system in the CNS. GABA binds its receptor and allows Cl‐ ions flow through the receptor in or out of the neuron. GAMS causes an amplification of the Cl‐ flow that causes symptoms. GAMSA binds to its receptor and counteracts the GAMS amplification of GABA and by that decrease symptoms.
Torbjörn Bäckström, Roshni Das, Marie Bixo   +2 more
wiley   +1 more source

Differential production of interleukin‐6 and tumor necrosis factor‐α in primary rat astrocyte cultures using two distinct methods of microglia elimination

Clinical and Experimental Neuroimmunology, Volume 12, Issue 3, Page 192-201, August 2021., 2021
This study examines the effect of the most important factors involved in hepatic encephalopathy on the production of reactive oxygen species and cytokines such as tumor necrosis factor‐α and interleukin‐6 in highly purified primary rat astrocyte cultures. Results demonstrated that manganese evoked oxidative stress in a time‐dependent manner.
Zoltan Barany, Istvan Toth, Gergely Jocsak, Laszlo V. Frenyo, Tibor Bartha, Agnes Sterczer, David S. Kiss   +6 more
wiley   +1 more source

Pediatric liver transplantation using a hepatitis B surface antigen-positive donor liver graft for congenital absence of the portal vein

Korean Journal of Transplantation, 2021
Congenital absence of the portal vein (CAPV) is a rare venous malformation in which mesenteric venous blood drains directly into systemic circulation. Herein, we report a case of pediatric deceased donor liver transplantation (DDLT) for symptomatic CAPV ...
Jung-Man Namgoong, Shin Hwang, Dae-Yeon Kim, Tae-Yong Ha, Gi-Won Song, Dong-Hwan Jung, Kyung Mo Kim, Seak Hee Oh   +7 more
doaj   +1 more source

Pharmacokinetics and Safety of Glasdegib in Participants With Moderate/Severe Hepatic Impairment: A Phase I, Single‐Dose, Matched Case‐Control Study

Clinical Pharmacology in Drug Development, Volume 10, Issue 7, Page 707-717, July 2021., 2021
Abstract This phase I open‐label trial (NCT03627754) assessed glasdegib pharmacokinetics and safety in otherwise healthy participants with moderate (Child‐Pugh B) or severe (Child‐Pugh C) hepatic impairment. Participants with hepatic impairment and age/weight‐matched controls with normal hepatic function received a single oral 100‐mg glasdegib dose ...
Joanna C. Masters, Robert R. LaBadie, Joanne Salageanu, Jerry Li, Naveed Shaik   +4 more
wiley   +1 more source